Futures on the Dow were significantly worse than the S&P 500 because of a cardiovascular drug’s late-stage setback.
Related stories
UK's third-biggest taxpayer to leave for Greece
The complicated implications of the spectacular ‘Apollo premium’
Singapore raises prime minister’s pay by $1mn
Mistral raises record €3bn as Europe strains to keep pace in AI race
'JLR job cuts a cause for uncertainty and worry'
Canada braces for prolonged trade war as counter-tariffs on US take effect